Altria Customer Services has submitted multiple patent applications related to vaping technology to the United States Patent and Trademark Office, including several that mention CBD and nicotine.
Credit goes to New Africa.
On August 4th, the company released three relevant applications, specifically focusing on CBD plants and their "flavor and aroma characteristics.
Altria Customer Service and the Virginia University Patent Foundation have submitted an application titled "Plant Terpene Production", which provides a detailed explanation of "ingredients and methods for altering the secondary metabolism functions of tobacco or CBD plant glandular trichomes, which control the formation of terpenes that impart specific flavors and aromatic characteristics to plant leaves." The piney or citrusy scent and flavor of cannabis buds are typical examples of terpene aromas.
The application stated that "by selectively manipulating gene expression in the terpene biosynthesis pathway, it is possible to enhance and modify the terpene levels in tobacco and CBD plants, improving the taste and aroma characteristics of downstream plant products.
The application stated that a related application titled "Increasing Trichome Density and Improving Metabolite Transport in Plant Trichomes...Terpenoid Plants are the Largest and Most Diverse Class of Plant Metabolites.
It further stated that, "The quantity of secondary metabolites produced is generally closely related to the density of glandular trichomes on the plant surface." "One method to increase the production of plant secondary metabolites is by increasing the density of trichomes on the plant epidermis.
The title of the third relevant application is "Promoters of Specific Tissues in Plants". According to the application, "Identification of preferred or specific trimeric promoters and corresponding cis-regulatory elements is required due to the important role of glandular trichomes in the biosynthesis and secretion of terpenoids.
In summary, these patent applications provide the clearest indication to date of Altria's interests and priorities in future CBD products. Altria acquired a significant stake in Canadian CBD company Cronos in 2019.
Statement:
This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.
This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the contents of the article. The compilation of this article is solely intended for industry communication and research.
Due to the limitations of the translator's ability, the translated article may not express the same meaning as the original. Therefore, readers should refer to the original article for accuracy.
2FIRSTS maintains full alignment with the Chinese government regarding any domestic, Hong Kong, Taiwan, or foreign-related statements and positions.
The compilation and distribution of this information is the property of the original media and its authors. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
